Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

Appointment of Andriy Mushak as the Fractional Chief Financial Officer

 

Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company"). Mr. Weichselbaum's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company's fractional Chief Financial Officer, effective as of June 6, 2026 (the "Effective Date").